Dr. Mager is Professor and Chair of Pharmaceutical Sciences at the University at Buffalo, State University of New York. He is also President and CEO of Enhanced Pharmacodynamics, LLC. He has served on the Pharmaceutical Sciences and Clinical Pharmacology Advisory Committee to the FDA and as a Visiting Professor at the University of Paris. He is a Fellow and Past-President of the International Society of Pharmacometrics and the American College of Clinical Pharmacology. Dr. Mager is also a Fellow of AAAS, AAPS, and FIP, the latter of which he serves as a Vice President. Dr. Mager is known for his contributions on theoretical concepts and models for target-mediated drug disposition, signal transduction, and combinatorial therapeutics, with a focus on anti-cancer and immunomodulatory agents. Current research efforts seek to combine network-based analysis with empirical, systems, and machine-learning models to explore anti-cancer drug regimens, heterogeneity in cancer and other therapeutic responses, and chemotherapy-induced adverse effects. He served as a Co-Editor of the book Systems Pharmacology and Pharmacodynamics and has contributed to 190+ peer-reviewed publications and book chapters. He is co-founder of Truvai Biosciences, LLC.